2025-11-15 - Analysis Report
Okay, here's a report analyzing TransMedics Group Inc. (TMDX) based on the provided data.

**TransMedics Group Inc. (TMDX) Analysis - November 16, 2025**

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) solutions for end-stage organ failure patients.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 185.62%
*   **VOO Cumulative Return:** 73.88%
*   **Spread (TMDX - VOO):**
    *   Current: 111.74%
    *   Max: 247.2%
    *   Min: -74.5%
    *   Relative Spread: 67.0 (Indicates TMDX's performance is in the upper range of its historical spread relative to VOO)

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD     | Alpha   | Beta  | Cap(B) |
|------------|-----------|---------|---------|-------|--------|
| 2019-2021  | -18.0%    | 83.5%   | -61.0%  | -0.0  | 0.7    |
| 2020-2022  | 94.0%     | 83.5%   | 95.0%   | 0.0   | 2.1    |
| 2021-2023  | 65.0%     | 80.5%   | 64.0%   | 0.1   | 2.7    |
| 2022-2024  | 130.0%    | 85.5%   | 109.0%  | 0.1   | 2.1    |
| 2023-2025  | 106.0%    | 85.5%   | 43.0%   | 0.3   | 4.0    |

**Analysis:**

*   TMDX has significantly outperformed the S&P 500 (VOO).  The large positive spread indicates substantial excess returns. A relative spread of 67.0 suggests that while TMDX's outperformance is strong, it's not at its historical peak relative to VOO.
*   The Alpha values are generally very high, suggesting that a substantial portion of the returns is independent of overall market movements.
*   Beta values are low, indicating relatively low correlation with the market. It increased over time, suggesting it is becoming more correlated
*   High MDD values are a cause for concern

**2. Recent Price Action**

*   **Current Price:** $115.01
*   **Previous Close:** $115.55
*   **Change:** -$0.47
*   **5-Day Moving Average:** $118.85
*   **20-Day Moving Average:** $125.14
*   **60-Day Moving Average:** $117.77

**Analysis:**

*   The price has decreased slightly (-$0.47).
*   The price is below all moving averages, suggesting a short-term downtrend.  The 5-day and 20-day MAs being significantly above the current price indicate potential further downward pressure.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 26.88 (Oversold)
*   **PPO:** -1.50 (Bearish Signal)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00)
*   **20-Day Relative Spread Change:** -5.5 (Short-term decline)
*   **Expected Return:** 42.8% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a medium investment risk.
*   The RSI indicates the stock is oversold, potentially signaling a buying opportunity.
*   The PPO is negative, confirming the bearish trend.
*   The hybrid signal recommends allocating available cash fully (100%) to purchase the stock, considering it a 'very safe' investment based on the MRI of 0.90. Moreover, it advises a monthly investment of 1.2% of the total investment.
*   The negative change in the 20-day relative spread reinforces the short-term downward trend.
*   The high expected return (42.8%) suggests that, despite current headwinds, the model projects significant outperformance over the S&P 500 in the long term (2+ years).
*   The price change of -$0.47, while not dramatic, combined with the other indicators, supports the current bearish sentiment.

**4. Recent News & Analyst Opinions**

*   **Recent News (Yahoo Finance):** The news headlines are predominantly positive, suggesting that the stock is potentially undervalued. Specifically, articles from Simply Wall St. highlight that TMDX shares could be significantly below their intrinsic value (potentially by as much as 50%). Other articles list TMDX among top value picks or stocks estimated to be trading below their fair value. One article mentions inducement grants, which is a neutral-to-slightly positive sign, indicating the company is incentivizing employees.
*   **Analyst Consensus:**
    *   Rating: Buy (~1.67 on a 1-5 scale)
    *   Opinions: 11
    *   Target Price: $141.91 (Average), $170.00 (High), $114.00 (Low)

**Analysis:**

*   Recent news flow strongly suggests the stock is undervalued, reinforcing the potential for long-term gains.
*   The analyst consensus is a "Buy" rating with an average target price significantly above the current price, supporting the undervaluation thesis. The low target price ($114.00) is slightly below the current price, indicating some analysts have a less optimistic outlook, but the overall sentiment remains positive.

**5. Overall Summary & Conclusion**

Based on the provided data, TransMedics Group Inc. (TMDX) presents a mixed picture:

*   **Strengths:**  Significant historical outperformance vs. S&P 500, high alpha, oversold conditions (RSI), positive analyst ratings, news indicating undervaluation, and a high expected return.
*   **Weaknesses:** Recent price weakness, short-term downtrend, negative PPO, a drop in relative spread and high MDD values.

**Recommendation:**

Despite the recent price weakness, the overall analysis suggests that TMDX could be an attractive investment opportunity for long-term investors. The stock appears to be undervalued based on analyst estimates and news reports. The oversold RSI and the positive long-term expected return support the idea of initiating or adding to a position, especially if the current downtrend reverses. It is advisable to consider dollar cost averaging given high MDD.

**Disclaimer:** This analysis is based solely on the provided information and does not constitute financial advice.  Investors should conduct their own due diligence before making any investment decisions.
